Mechanisms that affect reimbursement prices for medical devices in Japan, the world’s third largest medical device market: A scoping review

报销 医学 经皮冠状动脉介入治疗 传统PCI 医疗保健 财务 业务 心脏病学 经济 经济增长 心肌梗塞
作者
Satoru Hashimoto,Yoshihiro Motozawa,Takamitsu Mano
出处
期刊:International journal of healthcare management [Taylor & Francis]
卷期号:: 1-8 被引量:2
标识
DOI:10.1080/20479700.2023.2250612
摘要

ABSTRACTBackground Over the past two decades, Japanese reimbursement prices for medical devices used for percutaneous coronary intervention (PCI) were greatly reduced. This scoping review aimed to identify the mechanisms that influence the reimbursement prices of medical devices in Japan, such as devices used in cardiovascular diseases.Methods PubMed and Google Scholar were searched from their inception through July 31, 2022, for possible mechanisms that affect reimbursement in Japan.Results Reimbursement prices for PCI-related medical devices have declined since the middle of the 1990s because of the increasing number of PCI procedures performed due to an ageing society, differences in domestic and international prices, and differences between reimbursement prices and prevailing prices. In addition, the reimbursement price of medical devices is affected by the Health Technology Assessment, which considers the cost-effectiveness of medical devices and the market expansion re-pricing system, which is imposed on medical devices whose market has expanded significantly beyond the projections at the time of insurance listing.Conclusion Reimbursement prices of medical devices in Japan were primarily affected by three mechanisms aimed at controlling the healthcare expenditure; however, recently, in addition to these, the reimbursement price is evaluated from an economic perspective, including cost-effectiveness and market projection.Abbreviations: DES, Drug-eluting stent; EVAR, endovascular aneurysm repair; HTA, Health Technology Assessment; JFTC, Japanese Fair-Trade Commission; JROAD, Japanese registry of all cardiac and vascular disease; MHLW: Ministry of Health, Labor, and Welfare; NHRS, national health reimbursement system; PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation; TEVAR, thoracic endovascular aortic repairKEYWORDS: Reimbursementprice mechanismpercutaneous coronary interventionPCI-related medical deviceshealth technology assessment AcknowledgementsThe authors would like to thank Ms. Keiko Takahashi for her help in the preparation of the figures and tables, Ms. Rie Arai for her research assistance and Mr. Emmanuel Asika for the English language editing.Data availability statementAvailable upon the request.Disclosure statementNo potential conflict of interest was reported by the author(s).Contributors: Satoru Hashimoto made a concept, research, and design of the article. Dr. Yoshihiro Motozawa provided his clinical experience, interpret the data, and supported writing the article. Professor Toshiki Mano was responsible for final approval of the article to be submitted.Additional informationNotes on contributorsSatoru HashimotoSatoru Hashimoto BS, MBA after a consistent career in sales and marketing in the cardiovascular intervention field, founded TCROSS Co., Ltd, in 2005. He received his MBA from the Graduate School of Management, Globis University, in 2021. Hashimoto is currently studying medical innovation in a doctoral program at Chuo University.Yoshihiro MotozawaYoshihiro Motozawa MD, PhD after graduating from the University of Tokyo, School of Medicine, he began his clinical career as a cardiologist. He then went on to obtain his Ph.D. in Medicine from the University of Tokyo. He currently works at hospital as a clinician while working as a business consultant in TCROSS Co., Ltd.Toshiki ManoToshiki Mano MD, PhD After gaining clinical experience as a diabetes physician, Prof. Mano studied at Cornell University Medical School as a research fellow. He later earned an MBA from the University of Leicester Graduate School of Medicine in the UK while working in the management for a pharmaceutical company. Prof. Mano also holds a PhD in economics from Kyoto University. He is currently involved in the MBA education programs and serves as Chairman of the Hospital Committee of the Ministry of Health, Labor and Welfare, and the Japan Medical Association.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage应助科研通管家采纳,获得10
刚刚
JamesPei应助付冀川采纳,获得10
刚刚
1秒前
共享精神应助Q123ba叭采纳,获得10
1秒前
bkagyin应助科研通管家采纳,获得10
1秒前
1秒前
大个应助科研通管家采纳,获得10
1秒前
CipherSage应助科研通管家采纳,获得10
1秒前
华仔应助科研通管家采纳,获得10
1秒前
科目三应助科研通管家采纳,获得10
1秒前
Leo完成签到,获得积分10
1秒前
1秒前
充电宝应助科研通管家采纳,获得10
2秒前
科研通AI5应助科研通管家采纳,获得10
2秒前
万能图书馆应助期待未来采纳,获得10
2秒前
科研通AI5应助科研通管家采纳,获得10
2秒前
科研通AI2S应助科研通管家采纳,获得30
2秒前
酷波er应助科研通管家采纳,获得10
2秒前
非而者厚应助科研通管家采纳,获得10
2秒前
Hello应助科研通管家采纳,获得10
2秒前
完美世界应助科研通管家采纳,获得10
2秒前
科研通AI5应助科研通管家采纳,获得10
3秒前
非而者厚应助科研通管家采纳,获得10
3秒前
Luv_JoeyZhang完成签到 ,获得积分10
3秒前
3秒前
3秒前
练习者完成签到,获得积分10
4秒前
wlh完成签到,获得积分10
4秒前
SYLH应助RoyChen采纳,获得10
4秒前
WANG发布了新的文献求助10
4秒前
6秒前
6秒前
上官若男应助肖先生采纳,获得10
7秒前
Xiaoxiao应助任性代曼采纳,获得20
7秒前
8秒前
张怡博完成签到 ,获得积分10
8秒前
9秒前
9秒前
10秒前
11秒前
高分求助中
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 500
Arthur Ewert: A Life for the Comintern 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi // Kurt Werner Radtke 500
Two Years in Peking 1965-1966: Book 1: Living and Teaching in Mao's China // Reginald Hunt 500
Epigenetic Drug Discovery 500
Hardness Tests and Hardness Number Conversions 300
Knowledge management in the fashion industry 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3816802
求助须知:如何正确求助?哪些是违规求助? 3360159
关于积分的说明 10407045
捐赠科研通 3078172
什么是DOI,文献DOI怎么找? 1690613
邀请新用户注册赠送积分活动 813964
科研通“疑难数据库(出版商)”最低求助积分说明 767910